CArdiac STereotactic Radiation Treatment for Ablation of ventRicular Tachycardia
Key facts
- Who runs it
- Cancer Research Antwerp
- Where
- Antwerp and Edegem, BelgiumSee the 2 sites
- Trial code
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 25 Feb 2026
- Expected to end
- 25 Feb 2035
- Type of study
- Interventional
- Treatments tested
- Stereotactic body radiation therapy (SBRT)
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients over the age of 18 with structural heart disease
- Patients with ventricular tachycardia requiring intervention (e.g. an electrical shock or anti-tachycardia pacing via an Implantable Cardioverter Defibrillator (ICD)) which cannot be managed with medication or catheter ablation, or where there are contraindications to treatment with medication or catheter ablation
- Contraindications may exist due to comorbidities or due to the type or severity of the disease
- Informed consent to participate has been obtained from the patient or from his or her legal representative
Who cannot take part
- Previous radiotherapy that prevents the safe delivery of the dose
- Lack of evidence that the ventricular tachycardia is triggered by myocardial scarring (based on MRI, CT EAM)
- Any contraindication to radiosurgery (e.g. inability to precisely define the target volume due to imaging artefacts caused by an LVAD)
- Pregnancy
Where in Belgium
- ZAS AugustinusAntwerp, BelgiumContact: Ines Joye, PhDTaking people
- UZAEdegem, BelgiumContact: Johan Saenen, PhDTaking people
About the trial
What the trial wants to find out
The investigator-initiated, CArdiac Stereotactic radiation Treatment for Ablation of ventRicular tachycardia (CASTAR) study will be conducted in patients with ventricular tachycardia (VT) which is either refractory to antiarrhythmic medication therapy in maximal dose or to catheter ablation or with contraindications to antiarrhythmic medication or catheter ablation.
Read full original descriptionShow less
The study is a non-randomized, multicenter, interventional study of cardiac SBRT, for which a total dose of 25 Gy will be delivered in a single fraction using volumetric modulated arc therapy (VMAT). The aim of the CASTAR study is to assess the feasibility and the safety of cardiac SBRT for the treatment of VT. Secondary objectives are efficacy, toxicity and QoL of cardiac SBRT for Ventricular tachycardia .
The group in the trial
- SBRTTreatment being tested
A single radiation dose of 25 Gy is delivered to the VT target.
Treatment: Stereotactic body radiation therapy (SBRT)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 12 November 2026